Please login to the form below

Not currently logged in
Email:
Password:

cenegermin

This page shows the latest cenegermin news and features for those working in and with pharma, biotech and healthcare.

European Commission approves Dompé’s orphan drug

European Commission approves Dompé’s orphan drug

Oxervate will treat patients with neurotrophic keratitis. Italian biopharmaceutical company Dompé has received the go-ahead for Oxervate (cenegermin) for the treatment of moderate-to-severe neurotrophic keratitis (NK), a rare ... Researchers found that

Latest news

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Graphite Digital

We’re a digital CX agency collaborating with healthcare and pharmaceutical organisations to help them connect more deeply with their audiences...

Latest intelligence

Virtual Steering Committee & Peer Influence Program
In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program....
Meeting healthcare’s rising challenges
The journey to discover novel therapies through digital innovation and ensure scientific advances achieve their potential...
Report gives insights to address gaps in HCP engagement
How does Pharma-HCP engagement need to evolve in today's digital landscape?...